Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Cat. No. : PTAK-001
| Cat. No. | PTAK-001 |
| Description | The BACE1 Activity Assay Kit is designed to measure BACE1 activity for screening and profiling applications based on fluorescence resonance energy transfer (FRET) using a labeled peptide substrate. |
| Component |
•BACE1 •BACE assay buffer •BACE1 FRET peptide substrate •96-well plate |
| Applications | Useful for studying enzyme kinetics and screening small molecular inhibitors for drug discovery and HTS applications. |
| Size | 100 assays |
| Method | FRET |
| Caution | Avoid freeze/thaw cycles |
A: BACE1 is an enzyme that is involved in the production and clearance of beta-amyloid peptides, which are the main components of amyloid plaques found in the brains of individuals with Alzheimer's disease.
A: BACE1 cleaves amyloid precursor protein (APP) at a specific site, resulting in the formation of beta-amyloid peptides.
A: BACE1 plays a crucial role in the development of Alzheimer's disease. It is an enzyme responsible for cleaving amyloid precursor protein (APP) and releasing beta-amyloid (Aβ) peptides. The production and accumulation of Aβ peptides in the brain leads to the formation of amyloid plaques, which are a hallmark characteristic of Alzheimer's disease.
A: β-Site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors are potential disease-modifying drugs for the treatment of Alzheimer's disease (AD) because they prevent the production of synaptotoxic amyloid-β (Aβ).
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.